

RECORDATI: REGISTRATION WITH THE COMPANIES' REGISTER OF THE MERGER DEED BY ABSORPTION OF ROSSINI INVESTIMENTI S.P.A. AND FIMEI S.P.A. INTO RECORDATI S.P.A. COMPLETED

Milan, 22nd April 2021 – Following the press release issued on 12th April 2021, Recordati S.p.A. informs that, today, the last of the registrations of the merger deed relating to the merger by absorption of Rossini Investimenti S.p.A. and Fimeì S.p.A. into Recordati S.p.A. (the “**Merger Deed**” and the “**Merger**”, respectively), was completed with the competent Companies' Register of Milano, Monza, Brianza, Lodi.

Therefore, as provided for in the Merger Deed, the Merger will be effective for statutory purposes as of today, 22nd April 2021; as already communicated, the accounting and tax effects will be effective on 1st April 2021.

It is also to be recalled that, as a result of the completion of the Merger: (a) against cancellation of the 10,000,000 shares representing the entire share capital of Fimeì S.p.A., all held by Rossini Investimenti S.p.A., as well as of the 82,550,000 shares representing the entire share capital of Rossini Investimenti S.p.A. all held by Rossini S.àr.l., (b) all the 108,368,721 ordinary shares of Recordati S.p.A. (representing 51.820% of the share capital of the latter) previously held by Fimeì S.p.A., will be reassigned to Rossini S.àr.l., by updating the relevant accounting records and in the forms proper to the centralised management of shares in a dematerialised regime by Monte Titoli S.p.A., with the maintenance by third-party shareholders (i.e., other than Rossini S.àr.l. and Recordati S.p.A. itself) of the ordinary shares of Recordati S.p.A. held by them as at today.

The aforementioned Merged Deed is available to the public on Recordati's website www.recordati.com (in the area “Investors”, section ‘Shareholders’ Meetings – Reverse Merger into Recordati S.p.A. 2020/2021’).

***Recordati**, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and the other C.I.S. countries, Ukraine, Turkey, North Africa, the United States of America, Canada, Mexico, some South American countries, Japan and Australia. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in several therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2020 was € 1,448.9 million, operating income was € 469.0 million and net income was € 355.0 million.*

For further information:

Recordati website: www.recordati.com

[Investor Relations](#)

[Media Relations](#)

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1
20148 Milano, Italy
Ph. (39) 02 487871
Fax (39) 02 40073747
www.recordati.com

Share Capital € 26.140.644,50 fully paid-up
Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150
Tax Code/VAT No. 00748210150
Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.àr.l



Federica De Medici
(39) 02 48787146
e-mail: investorelations@recordati.it

Studio Noris Morano
(39) 02 76004736, (39) 02 76004745
e-mail: norismorano@studionorismorano.com